When the late-breaking abstracts from the European Society for Medical Oncology meeting in Madrid were released early last week, one of the more eagerly pored-over readouts was for Johnson & Johnson’s MARIPOSA study of its bispecific antibody product targeting EGFR and MET, Rybrevant, in non-small cell lung cancer (NSCLC).
The trial is a major part of the US company’s efforts to expand the market for Rybrevant (amivantamab) and challenge...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)